Koyfin Home > Directory > Health Care > Arena Pharmaceuticals > EBITDA Margin

Arena Pharmaceuticals EBITDA Margin Chart (ARNA)

Arena Pharmaceuticals annual/quarterly EBITDA Margin from 2000 to 2017. An EBITDA margin is a measurement of a company's earnings before interest, taxes, depreciation, and amortization as a percentage of its total revenue.
  • Arena Pharmaceuticals EBITDA Margin for the quarter ending December 12, 2017 was $-82m a -245.61% increase of 200m year over year
  • Arena Pharmaceuticals EBITDA Margin for the last 12 months ending September 09, 2017 was $5m a -18.07% decrease of -1m year over year
  • Arena Pharmaceuticals Annual EBITDA Margin for 2016 was $16m a 1,511.07% increase of 249m from 2015
  • Arena Pharmaceuticals Annual EBITDA Margin for 2015 was $-233m a -11.72% increase of 27m from 2014
  • Arena Pharmaceuticals Annual EBITDA Margin for 2014 was $-260m a 93.04% decrease of -242m from 2013
Other Margins & Efficiency Metrics:
  • Arena Pharmaceuticals Return on Capital % for the quarter ending September 09, 2018 was -14.88 a 16.87% decrease of -2.51 year over year
  • Arena Pharmaceuticals Return on Equity % for the quarter ending September 09, 2018 was -25.18 a -6.61% increase of 1.66 year over year
View Chart On Koyfin

Quarterly ARNA EBITDA Margin Data

12/2017$-82m
09/2017$-230m
06/2017$-299m
03/2017$-282m
09/2016$-38m
06/2016$-186m
03/2016$-170m
12/2015$-295m
09/2015$-248m
06/2015$-266m

Annual ARNA EBITDA Margin Data

2016$16m
2015$-233m
2014$-260m
2013$-18m
2012$-172m
2006$-275m
2005$-270m
2002$-161m
2001$-71m
2000$-138m